Results 1 to 10 of about 327,068 (394)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study [PDF]

Frontiers in Immunology, 2023
IntroductionClinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma ...
Ian Pavord, Frances Gardiner, Liam G. Heaney, Christian Domingo, Robert G. Price, Alison Pullan, John Oppenheimer, Guy Brusselle, Hiroyuki Nagase, Geoffrey Chupp, Emilio Pizzichini, Emilio Pizzichini, David Bañas-Conejero, Peter Howarth   +13 more
doaj   +3 more sources

Severe Eosinophilic Asthma [PDF]

Journal of Clinical Medicine, 2019
Asthma is a heterogeneous disease with varying severity. Severe asthma is a subject of constant research because it greatly affects patients’ quality of life, and patients with severe asthma experience symptoms, exacerbations, and medication side effects.
Agamemnon Bakakos, Stelios Loukides, Petros Bakakos   +2 more
openalex   +4 more sources

Severe eosinophilic asthma: a roadmap to consensus [PDF]

European Respiratory Journal, 2017
A task force has identified key consensus issues for defining, diagnosing and treating severe eosinophilic asthmahttp://ow.ly ...
Roland Buhl, Marc Humbert, Leif Bjermer, Pascal Chanez, Liam G. Heaney, Ian Pavord, Santiago Quirce, J. Christian Virchow, Stephen T. Holgate   +8 more
openalex   +6 more sources

Mepolizumab treatment in patients with severe eosinophilic asthma. [PDF]

New England Journal of Medicine, 2014
BACKGROUND Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocorticoids.
Hector G. Ortega, Mark C. Liu, I. Pavord, Guy Brusselle, J. FitzGerald, A. Chetta, M. Humbert, Lynn Katz, O. Keene, Steve W. Yancey, P. Chanez   +10 more
semanticscholar   +5 more sources

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) [PDF]

European Respiratory Journal, 2021
Background The long-term efficacy and safety of mepolizumab for treatment of severe eosinophilic asthma are well established. Here, we examine the clinical impact of stopping mepolizumab after long-term use.
Wendy C. Moore, Oliver Kornmann, Marc Humbert, Claude Poirier, Elisabeth H. Bel, Norihiro Kaneko, Steven G. Smith, Neil Martin, M Gilson, Robert G. Price, Eric Bradford, Mark C. Liu   +11 more
openalex   +2 more sources

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study. [PDF]

Respir Res, 2023
Background The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain.
Padilla-Galo A, Moya Carmona I, Ausín P, Carazo Fernández L, García-Moguel I, Velasco-Garrido JL, Andújar-Espinosa R, Casas-Maldonado F, Martínez-Moragón E, Martínez Rivera C, Vera Solsona E, Sánchez-Toril López F, Trisán Alonso A, Blanco Aparicio M, Valverde-Monge M, Valencia Azcona B, Palop Cervera M, Nuevo J, Sánchez Tena J, Resler G, Luzón E, Levy Naon A.   +21 more
europepmc   +2 more sources

Construction of Severe Eosinophilic Asthma Related Competing Endogenous RNA Network by Weighted Gene Co-Expression Network Analysis

Frontiers in Pharmacology, 2022
Background: Currently, disease control in patients with severe eosinophilic asthma is not optimistic. Competing endogenous RNA (ceRNA) networks have been found to play a key role in asthma in recent years.
Haixia Wang, Zeyi Zhang, Yu Ma, Yuanmin Jia, Bin Ma, Junlian Gu, Ou Chen, Ou Chen, Shouwei Yue, Shouwei Yue   +9 more
doaj   +2 more sources

Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. [PDF]

ERJ Open Res, 2023
Background The current definition of severe eosinophilic asthma (SEA) super-responders to biologic treatment does not include patients with other eosinophil-based comorbidities.
Portacci A, Campisi R, Buonamico E, Nolasco S, Pelaia C, Crimi N, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Scichilone N, Pelaia G, Crimi C, Carpagnano GE.   +18 more
europepmc   +2 more sources

Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity? [PDF]

International Journal of Molecular Sciences, 2021
Asthma is now recognized as a heterogeneous disease, encompassing different phenotypes driven by distinct pathophysiological mechanisms called endotypes.
Glenn Van Hulst, F. Bureau, C. Desmet
semanticscholar   +4 more sources

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma. [PDF]

BMJ Open Respir Res, 2023
Introduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD)
Chan R, Lipworth BJ.
europepmc   +2 more sources